GI
AVDL

GAMMA Investing’s Avadel Pharmaceuticals AVDL Stock Holding History

GAMMA Investing’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-650
Closed -$14K – 4119
2025
Q4 		$14K Buy
650
+47
+8% +$912 ﹤0.01% 2808
2025
Q3 		$9.21K Buy
603
+242
+67% +$3.15K ﹤0.01% 2918
2025
Q2 		$3.19K Sell
361
-9
-2% -$79 ﹤0.01% 3269
2025
Q1 		$2.9K Sell
370
-33
-8% -$276 ﹤0.01% 3288
2024
Q4 		$4.24K Sell
403
-880
-69% -$10.7K ﹤0.01% 2988
2024
Q3 		$16.8K Buy
1,283
+158
+14% +$2.41K ﹤0.01% 2204
2024
Q2 		$15.8K Buy
1,125
+61
+6% +$994 ﹤0.01% 2006
2024
Q1 		$18K Buy
1,064
+751
+240% +$11.2K ﹤0.01% 1723
2023
Q4 		$4.5K Buy
+313
New +$3.68K ﹤0.01% 2288

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

GAMMA Investing's AVDL Position: Q1 2026 in Review

GAMMA Investing sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 650 shares — an estimated $14K sold.

GAMMA Investing first reported a position in AVDL in Q4 2023 and held it in 9 quarters. The position peaked at $18K in Q1 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • GAMMA Investing reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • GAMMA Investing sold 650 Avadel Pharmaceuticals shares in Q1 2026, an estimated $14K.
  • GAMMA Investing first reported a position in Avadel Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • GAMMA Investing's Avadel Pharmaceuticals position peaked at $18K in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on GAMMA Investing's 13F filing for Q1 2026, filed 6 Apr 2026.